BioSpace News Archive

Business

Prevencio Announces Agreement with Alivio Health Expanding Access to AI-Driven Cardiac HART Tests Offered by Atlas Genomics

Prevencio, Inc. today announces that Atlas Genomics, Prevencio’s performing laboratory for its Artificial Intelligence (AI)-driven cardiac HART blood tests, has entered into a preferred provider agreement with Alivio Health to provide expanded access for Prevencio’s HART tests.

July 19, 2022
·
4 min read
Deals

Adhera Therapeutics Signs Letter of Intent to Acquire CD71-Targeted Cancer Therapy Paclitaxel Gallium Transferrin

Adhera Therapeutics, Inc. (OTCQB: ATRX) (“Adhera” or the “Company”), a clinical stage biopharmaceutical company, today announces that the Company has entered a Heads of Terms (also known as a Letter of Intent (“LOI”)) agreement with Bio Innovation Group to acquire Paclitaxel Gallium Transferrin (“PGT”).

July 19, 2022
·
5 min read
Drug Development

Capricor Therapeutics Announces First Patient Dosed in Pivotal Phase 3 Study of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy

Capricor Therapeutics today announced commencement of dosing in HOPE-3, a Phase 3 clinical trial investigating CAP-1002.

July 19, 2022
·
6 min read
Drug Development

Artelo Biosciences Completes Enrollment of the First Three Cohorts in its CAReS Study Evaluating ART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss

Artelo Biosciences, Inc. today announced the completion of enrollment of the first three cohorts in the Cancer Appetite Recovery Study (CAReS) and the initiation of a fourth cohort expected to complete the first stage of the Phase 1b clinical trial.

July 19, 2022
·
5 min read
Deals

LumiraDx Announces Proposed Public Offering of Common Shares

LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, today announced that it has commenced an underwritten public offering of 40,000,000 common shares.

July 19, 2022
·
5 min read
Drug Development

Kowa Pharmaceuticals America,Inc. Announces Publication of Phase 3 Data Supporting FDA Approval of SEGLENTIS®

Kowa Pharmaceuticals America,Inc. Announces Publication of Phase 3 Data Supporting FDA Approval of SEGLENTIS ® (celecoxib 56-mg and tramadol hydrochloride 44mg)CI-V as an Efficacious Alternative for Moderate-to-Severe Acute Pain in Appropriate Patients.

July 19, 2022
·
27 min read
Biotech Bay

New Study of Aerin Medical’s RhinAer® Shows Positive Clinical and Quality-of-Life Results Following Treatment for Chronic Rhinitis

Aerin Medical Inc., a company that provides Ear, Nose and Throat (ENT) physicians with non-invasive solutions to treat chronic nasal conditions, today announced the publication of positive results from the RELIEF clinical trial in the American Journal of Rhinology & Allergy.

July 19, 2022
·
5 min read
Biotech Bay

Vector Laboratories Launches Glysite™ Scout Glycan Screening Kits to Progress Glycobiology Research

Vector Laboratories , the pioneer of innovative proteomic and glycomic solutions, today announced the launch of its novel product Glysite™ Scout Glycan Screening Kits.

July 19, 2022
·
3 min read
Genetown

Paragonix Expands Research for Advanced Organ Preservation Clinical Registries

Paragonix Technologies , the leading hypothermic organ preservation provider, announced today its expanded enrollment in its GUARDIAN series of clinical registries aimed at investigating the impact of organ preservation.

July 19, 2022
·
3 min read
Biotech Bay

Medikine Initiates First Clinical Trial of its Lead Program, an Interleukin-7 Mimetic, Under Management Team with Expertise in Next-Generation Cytokine Drug Discovery and Development

Medikine, Inc., a biopharmaceutical company developing transformative therapeutics for cancer, autoimmune disorders, and infectious diseases using its novel PEPTIKINE™ technology, today announced it has initiated dosing of MDK-703, an extended half-life IL-7 mimetic.

July 19, 2022
·
6 min read